All
Patients Concerned as Humana Takes Herceptin Off Preferred Drug List in South Florida
January 30th 2018Until recently, Herceptin, which is used to treat patients with metastatic breast cancer, was fully covered under Humana’s South Florida Medicare Advantage plans. But, after taking it off the preferred drug list, patients will now be responsible for 20 percent of the drug’s cost, better aligning South Florida’s plans with Humana’s other Medicare Advantage plans.
Exploring Unanswered Questions on CAR-T Cell Therapy in Myeloma
January 29th 2018The success of CAR- (chimeric antigen receptor) T cell therapy is causing landmark change in the way that patients with multiple myeloma are being treated, but more research needs to be done to better understand the role that these agents will play.
Exploring Clonal Evolution in Colorectal Cancer
January 27th 2018Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.
Clinical Trial Scenarios Help to Appropriately Include Patients With Brain Metastases
January 23rd 2018Clinical trials designed to evaluate the use of anti-cancer drugs for the treatment of cancer typically exclude patients whose disease has spread to the brain or CNS for a number of reasons, including the misperception that they are poor clinical trial candidates.